Sun Pharma Advanced Research Company Limited — Others, 12-08-2025: Shareholders meeting

SPARC's shareholders approved all resolutions at the Annual General Meeting, including the re-appointment of the Chairman and CEO, and the appointment of new Independent Directors. Key approvals include adopting financial statements, enhancing a line of credit, and importantly, raising funds via equity shares, convertible warrants, or other instruments. The company highlighted pipeline progress for Sezaby, SCD-153, and SBO-154. Vodobatinib's neurodegenerative program is paused, with focus shifting to oncology licensing. SPARC emphasized a sharper strategic focus, exploring collaborations, and the need for additional capital or reduced cash burn to advance its early-stage, high-investment pipeline assets.